title: Epidermal growth factor receptor inhibits colitis-associated cancer in mice.
abstract: Inflammatory bowel disease (IBD) is a chronic illness caused by complex interactions between genetic and environmental factors that propagate inflammation and damage to the gastrointestinal epithelium. This state of chronic inflammation increases the risk for development of colitis-associated cancer in IBD patients. Thus, the development of targeted therapeutics that can disrupt the cycle of inflammation and epithelial injury is highly attractive. However, such biological therapies, including those targeting epidermal growth factor receptor pathways, pose a risk of increasing cancer rates. Using two mouse models of colitis-associated cancer, we found that epidermal growth factor receptor inactivation accelerated the incidence and progression of colorectal tumors. By modulating inflammation and epithelial regeneration, epidermal growth factor receptor optimized the response to chronic inflammation and limited subsequent tumorigenesis. These findings provide important insights into the pathogenesis of colitis-associated cancer and suggest that epidermal growth factor-based therapies for IBD may reduce long-term cancer risk.
authors: The Saban Research Institute of Children’s Hospital Los Angeles, Los Angeles, CA, USA.
authors: Philip E
authors: PE
authors: Dubé
authors: Fang
authors: F
authors: Yan
authors: Shivesh
authors: S
authors: Punit
authors: Nandini
authors: N
authors: Girish
authors: Steven J
authors: SJ
authors: McElroy
authors: M Kay
authors: MK
authors: Washington
authors: D Brent
authors: DB
authors: Polk
mesh_terms: D000818:Animals; D003092:Colitis / Q000150:complications* / Q000473:pathology / Q000503:physiopathology* / Q000517:prevention & control; D003106:Colon / Q000276:immunology / Q000503:physiopathology; D015179:Colorectal Neoplasms / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control*; D016207:Cytokines / Q000235:genetics; D004195:Disease Models, Animal; D018450:Disease Progression; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D020869:Gene Expression Profiling; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D016753:Interleukin-10 / Q000172:deficiency / Q000235:genetics; D051379:Mice; D018345:Mice, Knockout; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D012307:Risk Factors; D015398:Signal Transduction; D025521:Tumor Suppressor Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology
chemical_list: D016207:Cytokines; C556062:IL10 protein, mouse; D025521:Tumor Suppressor Proteins; D016753:Interleukin-10; D066246:ErbB Receptors; C482120:Braf protein, mouse; D048493:Proto-Oncogene Proteins B-raf